Fulltext

Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a Population-Based HIV/AIDS Treatment Program

Braitstein, Paula ; Zala, Carlos ; Yip, Benita ; Brinkhof, Martin W. G. ; Moore, David ; Hogg, Robert S. ; Montaner, Julio S. G.

In: Journal of Infectious Diseases, 2006, vol. 193, no. 2, p. 259-268

Ajouter à la liste personnelle
    Titre
    • Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a Population-Based HIV/AIDS Treatment Program
    Auteur
    • Braitstein, Paula. British Columbia Centre for Excellence in HIV/AIDS and Departments of
    • Zala, Carlos. Fundacion Huesped, Buenos Aires, Argentina
    • Yip, Benita. British Columbia Centre for Excellence in HIV/AIDS and Departments of
    • Brinkhof, Martin W. G.. Institute of Social and Preventive Medicine, University of Berne, Berne, Switzerland
    • Moore, David. British Columbia Centre for Excellence in HIV/AIDS and Departments of
    • Hogg, Robert S.. British Columbia Centre for Excellence in HIV/AIDS and Departments of
    • Montaner, Julio S. G.. British Columbia Centre for Excellence in HIV/AIDS and Departments of
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Infectious Diseases, 2006, vol. 193, no. 2, p. 259-268. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290589
    Summary
    BackgroundWe sought to characterize the impact that hepatitis C virus (HCV) infection has on CD4 cells during the first 48 weeks of antiretroviral therapy (ART) in previously ART-naive human immunodeficiency virus (HIV)-infected patients MethodsThe HIV/AIDS Drug Treatment Programme at the British Columbia Centre for Excellence in HIV/AIDS distributes all ART in this Canadian province. Eligible individuals were those whose first-ever ART included 2 nucleoside reverse transcriptase inhibitors and either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor and who had a documented positive result for HCV antibody testing. Outcomes were binary events (time to an increase of ⩾75 CD4 cells/mm3 or an increase of ⩾10% in the percentage of CD4 cells in the total T cell population [CD4 cell fraction]) and continuous repeated measures. Statistical analyses used parametric and nonparametric methods, including multivariate mixed-effects linear regression analysis and Cox proportional hazards analysis ResultsOf 1186 eligible patients, 606 (51%) were positive and 580 (49%) were negative for HCV antibodies. HCV antibody-positive patients were slower to have an absolute (P<.001) and a fraction (P=.02) CD4 cell event. In adjusted Cox proportional hazards analysis (controlling for age, sex, baseline absolute CD4 cell count, baseline pVL, type of ART initiated, AIDS diagnosis at baseline, adherence to ART regimen, and number of CD4 cell measurements), HCV antibody-positive patients were less likely to have an absolute CD4 cell event (adjusted hazard ratio [AHR], 0.84 [95% confidence interval {CI}, 0.72-0.98]) and somewhat less likely to have a CD4 cell fraction event (AHR, 0.89 [95% CI, 0.70-1.14]) than HCV antibody-negative patients. In multivariate mixed-effects linear regression analysis, HCV antibody-negative patients had increases of an average of 75 cells in the absolute CD4 cell count and 4.4% in the CD4 cell fraction, compared with 20 cells and 1.1% in HCV antibody-positive patients, during the first 48 weeks of ART, after adjustment for time-updated pVL, number of CD4 cell measurements, and other factors ConclusionHCV antibody-positive HIV-infected patients may have an altered immunologic response to ART